

### In the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:


Claims 1-26 are pending in this Application.

Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, and 24 **(currently amended)**

Claims 10, 11, 20, 21, 22, 23, 25, and 26 **(cancelled)**

Claims 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, and 38 **(new)**

1. **(currently amended)** A compound represented by formula I,



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt, ~~hydrate, or prodrug~~ thereof, and wherein,

each W is independently N or CR<sup>1</sup>;

each R<sup>1</sup> is independently selected from -H, halogen, trihaloalkyl, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, ~~NC(O)R<sup>6</sup>, NCO<sub>2</sub>R<sup>6</sup>~~, -C(O)R<sup>7</sup>, -R<sup>7</sup>, and -A-R<sup>7</sup>; provided at least one of R<sup>1</sup> is -A-R<sup>7</sup>, wherein, only for said at least one -A-R<sup>7</sup>, R<sup>7</sup> must be an ~~optionally substituted~~ heteroalicyclic ring, and any nitrogen of said optionally substituted heteroalicyclic ring cannot be directly bound to A, and where the heteroalicyclic ring of -A-R<sup>7</sup> is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy,

substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

A is O, S(O)<sub>0-2</sub>, and NR<sup>6</sup>;

L is O, S(O)<sub>0-2</sub>, or NR<sup>3</sup>;

Q is C or N, when Q is N, then R<sup>4</sup> does not exist;

R<sup>2</sup> and R<sup>3</sup> are each independently -H or -R<sup>7</sup>;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, ~~NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>,~~ -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, halogen, trihalomethyl, and -R<sup>7</sup>; or

R<sup>4</sup> and R<sup>5</sup>, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R<sup>15</sup>;


R<sup>6</sup> is selected from -H, ~~optionally substituted~~ C<sub>1-8</sub>alkyl, ~~optionally substituted~~ arylC<sub>1-8</sub>alkyl, ~~optionally substituted~~ heterocyclylC<sub>1-8</sub>alkyl, ~~optionally substituted~~ aryl, and ~~optionally substituted~~ heterocyclyl;

R<sup>7</sup>, for other than R<sup>7</sup> in -A-R<sup>7</sup>, is selected from -H, ~~optionally substituted~~ C<sub>1-8</sub>alkyl, ~~optionally substituted~~ arylC<sub>1-8</sub>alkyl, ~~optionally substituted~~ heterocyclylC<sub>1-8</sub>alkyl, ~~optionally substituted~~ aryl, and ~~optionally substituted~~ heterocyclyl; provided that there are at least two carbons between any heteroatom of R<sup>7</sup> and A ~~or~~ either nitrogen to which R<sup>2</sup> [[or ]]and R<sup>3</sup> are attached; or

R<sup>6</sup> and R<sup>7</sup>, when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ five- to seven-membered heterocyclic ring, said ~~optionally substituted~~ five- to seven-membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;

R<sup>8</sup> is -H, -NO<sub>2</sub>, -CN, -OR<sup>6</sup>, and ~~optionally substituted~~ C<sub>1-8</sub>alkyl;

X is selected from one of the following six formulae:



wherein m is zero to five, n is zero to three, and Z is N or CR<sup>10</sup>;

R<sup>10</sup> is selected from -H, halogen, trihalomethyl, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and R<sup>7</sup>;

K is O, S, or NR<sup>11</sup>;

R<sup>11</sup> is selected from cyano, -NO<sub>2</sub>, -OR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(O)R<sup>7</sup>, and R<sup>6</sup>; and

each R<sup>15</sup> is independently selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and R<sup>7</sup>.

2. **(currently amended)** The compound according to claim 1, wherein L is NR<sup>3</sup>; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

3. **(currently amended)** The compound according to claim 2, wherein K is either O or NR<sup>11</sup>; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

4. **(currently amended)** The compound according to claim 3, wherein R<sup>2</sup> and R<sup>3</sup> are each independently selected from -H and ~~optionally substituted C<sub>1-8</sub>alkyl~~, ~~wherein~~

~~substitution on the C<sub>1-8</sub>alkyl of optionally substituted C<sub>1-8</sub>alkyl is selected from NH<sub>2</sub>, NO<sub>2</sub>, OR<sup>6</sup>, N=CNR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>R<sup>7</sup>, N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, SR<sup>6</sup>, S(O)<sub>1-2</sub>R<sup>6</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, CO<sub>2</sub>R<sup>6</sup>, C(O)NR<sup>6</sup>R<sup>7</sup>, C(O)N(OR<sup>6</sup>)R<sup>7</sup>, C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, NC(O)R<sup>6</sup>, NCO<sub>2</sub>R<sup>6</sup>, C(O)R<sup>7</sup>, heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.~~


5. **(currently amended)** The compound according to claim 4, wherein R<sup>2</sup> and R<sup>3</sup> are -H; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

6. **(currently amended)** The compound according to claim 5, wherein only one of R<sup>1</sup> is -A-R<sup>7</sup>, where A is selected from O, S(O)<sub>0-1</sub>, and NR<sup>6</sup>; and for -A-R<sup>7</sup>, R<sup>7</sup> is an optionally substituted heteroalicyclic ring optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

7. **(currently amended)** The compound according to claim 6, wherein R<sup>6</sup> is selected from -H and C<sub>1-8</sub>alkyl; ~~said C<sub>1-8</sub>alkyl optionally substituted with one or more groups each independently selected from NH<sub>2</sub>, NO<sub>2</sub>, OR<sup>6</sup>, N=CNR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>R<sup>7</sup>, N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, SR<sup>6</sup>, S(O)<sub>1-2</sub>R<sup>6</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, CO<sub>2</sub>R<sup>6</sup>, C(O)NR<sup>6</sup>R<sup>7</sup>, C(O)N(OR<sup>6</sup>)R<sup>7</sup>, C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, NC(O)R<sup>6</sup>, NCO<sub>2</sub>R<sup>6</sup>, C(O)R<sup>7</sup>, heterocyclic, alicyclic, and aryl; and R<sup>7</sup> of -A-R<sup>7</sup> is selected from the following optionally substituted heteroalicyclics: azetidine, perhydroazepinyl, piperidinyl, piperazinyl, azabicyclo[3.2.1]octyl, octahydro-cyclopenta[c]pyrroleyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolidinyl, dihydropyridinyl, tetrahydropyridinyl, quinuclidinyl,~~


tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl sulfone, and dioxaphospholanyl; where the heteroalicyclic is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

8. (currently amended) The compound according to claim 7, wherein X is



m is 0 to 3, and  $R^{10}$  is selected from -H, halogen,  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-NC(O)R^6$ ,  $-NCO_2R^6$ ,  $-C(O)R^7$ , and optionally substituted  $C_{1-8}$ alkyl; said  $C_{1-8}$ alkyl optionally substituted with one or more groups each independently selected from  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-NC(O)R^6$ ,  $-NCO_2R^6$ ,  $-C(O)R^7$ , heterocyclic, alicyclic, and aryl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. (currently amended) The A compound according to ~~claim 8~~, of formula II:



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A, R<sup>4</sup>, R<sup>5</sup>, R<sup>10</sup>, and m are as defined above;

A is selected from O, S(O)<sub>0-1</sub>, and NR<sup>6</sup>;

R<sup>7</sup>, in -A-R<sup>7</sup>, is selected from ~~optionally substituted~~ perhydroazepinyl, ~~optionally substituted~~ piperidinyl, ~~optionally substituted~~ pyrrolidinyl, and ~~optionally substituted~~ azetidine; wherein the ring nitrogen of R<sup>7</sup> is substituted with a group R<sup>12</sup>; and R<sup>12</sup> is selected from a) -H, b) ~~optionally substituted~~ C<sub>1-8</sub>alkyl, c) -SO<sub>2</sub>R<sup>6</sup>, d) -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, e) -CO<sub>2</sub>R<sup>6</sup>, f) -C(O)NR<sup>6</sup>R<sup>7</sup>, g) -C(O)R<sup>7</sup>, and h) ~~an optionally substituted~~ three- or four-carbon bridge between the ring nitrogen of R<sup>7</sup> and a carbon vicinal to the ring nitrogen of R<sup>7</sup>; said three- or four-atom bridge optionally containing an oxygen in substitution for a carbon of the bridge; and where the C<sub>1-8</sub>alkyl in b) and the bridge in h) are optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

R<sup>6</sup> is selected from -H and C<sub>1-8</sub>alkyl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, halogen, trihalomethyl, and -R<sup>7</sup>; or

R<sup>4</sup> and R<sup>5</sup>, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R<sup>15</sup>;

R<sup>10</sup> is selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and C<sub>1-8</sub>alkyl;

m is 0 to 3;

R<sup>7</sup>, for other than R<sup>7</sup> in A-R<sup>7</sup>, is selected from -H, C<sub>1-8</sub>alkyl, arylC<sub>1-8</sub>alkyl, heterocyclylC<sub>1-8</sub>alkyl, aryl, and heterocyclyl;


R<sup>8</sup> is -H, -NO<sub>2</sub>, -CN, -OR<sup>6</sup>, and C<sub>1-8</sub>alkyl; and

each R<sup>15</sup> is independently selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and R<sup>7</sup>.

10. (canceled)

11. (canceled)

12. (currently amended) A The compound according to elaim 11, of formula III.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R<sup>12</sup> is a C<sub>1-4</sub>alkylene;

R<sup>13</sup> is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and an heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R<sup>12</sup> which is directly attached to the ring nitrogen of the piperidine in formula III;





$R^{10}$  is[[ is]] selected from -H, halogen, perfluoroalkyl,  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  ~~$-NC(O)R^6$ ,  $-NCO_2R^6$~~ ,  $-C(O)R^7$ ;

$R^4$  and  $R^5$  are each independently selected from -H, halogen, and  $C_{1-4}$ alkyl; or  $R^4$  and  $R^5$  combined are ~~an optionally substituted phenyl~~ where the phenyl is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl,

heterocyclylalkyl, heterocyclyl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino; and

m is 0-3;

$R^6$  is selected from -H and  $C_{1-8}$ alkyl, said  $C_{1-8}$ alkyl substituted with at least one of  $-CO_2H$  and  $-CO_2C_{1-8}$ alkyl;

$R^7$  is selected from -H,  $C_{1-8}$ alkyl,  $arylC_{1-8}$ alkyl,  $heterocyclylC_{1-8}$ alkyl, aryl, and heterocyclyl; and

$R^8$  is -H,  $-NO_2$ ,  $-CN$ ,  $-OR^6$ , and  $C_{1-8}$ alkyl.

14. **(currently amended)** The compound according to claim 13, wherein  $R^{12}$  is an ethylene;  $R^{10}$  is halogen;  $R^4$  and  $R^5$  are each independently selected from -H, halogen, and  $C_{1-2}$ alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

15. **(currently amended)** The compound according to claim 14, wherein each  $R^{10}$  is independently selected from fluorine and chlorine;  $R^4$  and  $R^5$  are each independently selected from -H and  $C_{1-2}$ alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(currently amended)** The compound according to claim 15, wherein each  $R^{10}$  is independently selected from fluorine and chlorine;  $R^4$  and  $R^5$  are each independently selected from -H and  $-CH_3$ ; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.






17. **(currently amended)** The compound according to claim 16, wherein R<sup>10</sup> is fluorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and -CH<sub>3</sub>; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

18. **(currently amended)** The compound according to claim[[ 1]] 17, selected from the following:

Entry	Name	Structure
1	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one	
2	(3Z)-5-[[1-ethylpiperidin-3-yl]amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
3	(3Z)-5-[[1-ethylpiperidin-4-yl]amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
4	(3Z)-5-[[1-ethylpiperidin-4-yl]amino]-3-[1H-imidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-methylphenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
8	(3Z)-3-[1H-benzimidazol-2-yl(4-(methoxy)phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
10	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
20	3-((Z)-1H-benzimidazol-2-yl)(5-((1-ethylpiperidin-4-yl)amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzonitrile	
21	(3Z)-3-((3-aminophenyl)(1H-benzimidazol-2-yl)methylidene)-5-((1-ethylpiperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	
22	(3Z)-3-((1H-benzimidazol-2-yl)(phenyl)methylidene)-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
23	3-((Z)-1H-benzimidazol-2-yl)(5-((1-ethylpiperidin-4-yl)amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzenecarboximide	
24	(3Z)-3-((1H-benzimidazol-2-yl)(phenyl)methylidene)-5-((1-(2-(methyloxy)ethyl)piperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
28	2-[2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)(phenyl)methyl}-1H-imidazol-4-yl}ethyl]-1H-isoindole-1,3(2H)-dione	
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-[2-(dimethylamino)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
32	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[[1-ethylpiperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[[1-ethylpiperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(phenylmethyl)piperidin-4-yl]oxy]-1,3-dihydro-2H-indol-2-one	








Entry	Name	Structure
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
39	(3Z)-3-[1H-benzimidazol-2-yl(3-(methyloxy)phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(1H-imidazol-2-yl)(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-methylphenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[1H-imidazol-2-yl][6-(trifluoromethyl)pyridin-3-yl]methylidene]-1,3-dihydro-2H-indol-2-one	
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



Entry	Name	Structure
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
84	(3Z)-5-[(1-[2-(diethylamino)ethyl]piperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	






Entry	Name	Structure
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[[1-(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
88	ethyl 2-[(Z)-(3-fluorophenyl)[5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl]-4-methyl-1H-imidazole-5-carboxylate	
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-[[1-[2-(methyloxy)ethyl]piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
90	(3Z)-3-{1H-imidazol-2-yl}[4-(methoxy)phenyl]methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-(methylsulfonyl)piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
94	(3Z)-3-[1H-imidazol-2-yl](4-propylphenyl)methylidene]-5-({1-[2-(methoxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
98	(3Z)-3-[1H-imidazol-2-yl]-6-(trifluoromethyl)pyridin-3-ylmethylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	 <u>and</u>
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

Entry	Name	Structure
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



Entry	Name	Structure
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof

19. **(currently amended)** A pharmaceutical composition comprising a compound according to any one of claims 1-18 claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound of claim 1, 9, 12, 13, 18, 31, 32, 33, 34, 35, 36, 37, or 38 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; or comprising administering, to a mammal in need thereof, a therapeutically effective amount of the pharmaceutical composition as described in any one of claims 1-19 of claim 19.

25. (canceled)

26. (canceled)

27. (new) The method of Claim 24 where the disease or disorder is cancer.






28. (new) The method of Claim 27 where the cancer is non-small cell lung cancer, renal cell carcinoma, cancer of the large bowel, gastrointestinal cancer, ovarian cancer, acute myeloid leukemia, and multiple myeloma.






29. (new) The method of Claim 27 where the cancer is selected from squamous cell cancer, undifferentiated large cell cancer, adenocarcinoma, and alveolar (bronchiolar) carcinoma.



30. (new) The method of Claim 24 where the disease or disorder is atherosclerosis.

31. (new) The compound of Claim 7 selected from

10	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
----	--	--




25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene]-1,3-dihydro-2H-indol-2-one	






99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	






114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	 and
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

32. (new) The compound of Claim 9 selected from

1	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one	
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
30	(3Z)-3-[1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	

32	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-(phenylmethyl)piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	

37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

33. (new) The compound of Claim 12 selected from

6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	



50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methoxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

88	ethyl 2-((Z)-(3-fluorophenyl)[5-((1-[2-(methyloxy)ethyl]piperidin-4-yl)amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-4-methyl-1H-imidazole-5-carboxylate	
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-((1-[2-(methyloxy)ethyl]piperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-((1-[2-(methyloxy)ethyl]piperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	 and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-((1-[2-(methyloxy)ethyl]piperidin-4-yl)amino)-1,3-dihydro-2H-indol-2-one	







and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.






34. (new) The compound of Claim 13 selected from

3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
8	(3Z)-3-[1H-benzimidazol-2-yl[4-(methoxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
21	(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
23	3-((Z)-1H-benzimidazol-2-yl(5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzenecarboximide	

24	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
39	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	










61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	 and
90	(3Z)-3-[1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.






35. (new) The compound of Claim 16 selected from

40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-([1-[2-(methyloxy)ethyl]piperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-([1-ethylpiperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-([1-ethylpiperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-([1-ethylpiperidin-4-yl]amino)-1,3-dihydro-2H-indol-2-one	

109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	 and
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	


and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, and where the compound is optionally as a pharmaceutically acceptable salt thereof.

36. (new) A compound selected from

20	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl}benzonitrile	
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
98	(3Z)-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	


	<p>7-[(1<i>H</i>-Benzoimidazol-2-yl)-(3-chloro-phenyl)-methylene]-2-[1-(2-methoxy-ethyl)-piperidin-4-ylamino]-5,7-dihydro-pyrrolo[3,2-<i>d</i>]pyrimidin-6-one</p>	
	<p>E- and Z- of 3-[(1<i>H</i>-Benzoimidazol-2-yl)-(3-chloro-phenyl)-methylene]-5-[1-(2-methoxy-ethyl)-piperidin-4-yloxy]-1,3-dihydro-pyrrolo[3,2-<i>b</i>]pyridin-2-one</p>	

37. (new) The compound of Claim 18 selected from

<p>(3<i>Z</i>)-3-[(2-fluorophenyl)(4-methyl-1<i>H</i>-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2<i>H</i>-indol-2-one</p>	
---	---

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

38. (new) The compound of Claim 18 selected from

<p>(3<i>Z</i>)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1<i>H</i>-imidazol-2-yl)methylidene]-1,3-dihydro-2<i>H</i>-indol-2-one</p>	
---	--

and a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.